Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427895 | 0.90 | SMN1; SMN2 (0.49) | ITGB1ITGA4SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7425039 | 0.87 | ITGB1 (0.54) | ITGB1ITGA4SMN1; SMN2KMT2A | |
| SCHEMBL7430007 | 0.86 | ITGB1 (0.49) | ITGB1ITGA4SMN1; SMN2KMT2A | |
| SCHEMBL7426841 | 0.82 | ITGA4 (0.51) | ITGB1ITGA4SMN1; SMN2KMT2ACCR3 | |
| SCHEMBL7481020 | 0.81 | RAB9A (0.52) | ITGB1ITGA4SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7431414 | 0.79 | ACHE (0.54) | ITGB1ITGA4SMN1; SMN2KMT2A | |
| SCHEMBL7430185 | 0.78 | ITGB1 (0.45) | ITGB1ITGA4KMT2ACCR3 | |
| SCHEMBL7429189 | 0.77 | ITGB1 (0.62) | ITGB1ITGA4SMN1; SMN2 | |
| SCHEMBL7429200 | 0.76 | ITGB1 (0.53) | ITGB1ITGA4SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7385295 | 0.74 | KMT2A (0.50) | ITGB1ITGA4SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |